Veracuity is changing the current paradigm in pharmacovigilance through a cloud-based platform eVERA that captures, processes, and analyzes adverse events, with the ultimate goal of providing consumers, healthcare professionals and manufacturers, with abundant real-world evidence, enabling a better understanding of the benefits, risks and safety of their products.
The current practice of drug safety surveillance is fraught with challenges and limitations, but new technologies, perspectives, and concerns are shaping the way stakeholders will need to conduct this crucial activity in the coming years. We empower physicians and patients with accurate and reliable information about the products they use in the context of clinical care. To achieve this, we streamline, simplify and automate the processing of adverse drug events, while reducing costs of data capture and processing. We link reported information with additional data sources to enrich the dataset and produce actionable intelligence for our customers. Accurate and timely insight into the true performance of pharmaceutical products in the clinical context is an essential prerequisite needed to reduce liability associated with avoidable patient harm.
Name Veracuity is amalgamation of Veracity and Acuity which means truth and focus. We value truth and transparency so that people can make informed decisions. We are compassionate,respectful of privacy and trustful.
Veracuity Team consists of industry veterans who spent their careers performing all aspects of clinical research and pharmacovigilance activities. The experiences of the Team members, collectively, cover the full scope of the current drug safety surveillance activities and processes. This deep domain knowledge combined with a keen interest in new technologies makes the Veracuity Team uniquely qualified to redesign the drug safety surveillance system to better serve the stakeholders’ information needs.
Dr. Jonathan Fishbein is a surgeon and transplant immunologist by training. He has held various leadership positions at leading contract research organizations for most of his 30+ year career, most recently Sr. Vice President for Safety and Commercialization at PRA Health Sciences. He was the first Director of the Office for Policy in Clinical Research Operations at the NIAID Division of AIDS from 2003 to 2005.
Dr. Sreeram Penna has more than 15 years of experience as a clinician and researcher. He worked in orthopedic surgery and his research interests include big data, machine learning and artificial intelligence concepts in health care. He has experience in generating real world evidence using social media data to be used in health care research. He would like to bring this experience to pharmacovigilance.
Dr. Veronika Valdova, a veterinarian by education spent most of her career in various roles in drug safety and clinical research. Her experience includes all aspects of pharmacovigilance operations from case processing to compiling safety reports and analyses and reviewing and evaluating scientific literature. She is passionate about the operational costs of drug safety surveillance and the quality of intelligence drug safety monitoring activities can provide.
Jonanthan Strong has been in every IT role over 40 years from architect through CIO several times. He has led $150M consulting teams, advising CIOs and private equity for startups through $60B global firms, as well as leading award-winning global transformation for them. He has deep experience in life sciences, FinTech, manufacturing, and leading edge technology, changing IT from a cost center to a strategic investment and competitive differentiator.
Michael Marschler is a pharmacovigilance expert by training. He worked in various roles in the Pharmaceutical and CRO industries. His experience includes all aspects of pharmacovigilance from case processing and aggregate safety reporting to risk management and signal management, as well as process development to ensure regulatory compliance. During the last years he focuses on pharmacogenomics and how to integrate PGx within pharmacovigilance. He served as EU QPPV and most recently as Sr. Director Pharmacovigilance and Global Head of Patient Safety Operations at PRA Health Sciences.
Mr. Packman was previously Chief Development Officer of Clementia Pharmaceuticals. At Clementia he led the successful execution of the company’s palovarotene drug development program in Fibrodysplasia Ossificans Progressiva. FOP is an ultra-rare and severely disabling condition characterized by the abnormal growth of bone in muscles, tendons and ligaments causing severe disability and early death. In 2018, Clementia received agreement from the US Food and Drug Administration to submit an early application for approval of palovarotene in FOP based on the Phase 2 data generated by the company. Subsequent to this agreement, Clementia was acquired by Ipsen in April 2019.
Prior to Clementia, Mr. Packman led drug development efforts at several biotechnology companies. Most recently, he served as Chief Development Officer for Apofore Corporation, a start-up focused on the development of novel diabetes therapeutics. Prior to Apofore, Mr. Packman was Vice President of Drug Development Operations at FoldRx Pharmaceuticals, which was acquired by Pfizer in October 2010. He was development team leader for Vyndaqel® (tafamidis), now approved worldwide for the treatment of transthyretin cardiac amyloidosis and in many jurisdictions for the rare disease transthyretin familial amyloid polyneuropathy. Mr. Packman also headed development operations at Oscient Pharmaceuticals and worldwide business operations for the regulatory affairs division of PAREXEL International Corporation.